Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors - Centre de recherche des Cordeliers Access content directly
Journal Articles (Review Article) OncoImmunology Year : 2023

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors

Abstract

ecent clinical trials have compared the use of different chemotherapeutic regimens as "immune induction therapies" to sensitize cancers to immune checkpoint inhibitors (ICI). Cytotoxic drugs reputed to be inducers of immunogenic cell death (ICD) appeared to be particularly efficient for this purpose. A trial published in Nature Medicine by Thibaudin et al. reveals the capacity of oxaliplatin-based chemotherapy to sensitize RAS-mutant unresectable metastatic colorectal cancer to ICIs blocking CTLA-4 and PD-L1.
Fichier principal
Vignette du fichier
10732660.pdf (236.61 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04596691 , version 1 (06-06-2024)

Identifiers

Cite

Lucillia Bezu, Oliver Kepp, Guido Kroemer. Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors. OncoImmunology, 2023, 12 (1), pp.2272352. ⟨10.1080/2162402X.2023.2272352⟩. ⟨hal-04596691⟩
36 View
3 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More